Impact of Acceptance and Commitment Therapy on Salivary Cortisol in Breast Cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Breast Neoplasms
- Sponsor
- San Jose State University
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- salivary cortisol
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this randomized controlled trial is to evaluate the effectiveness of an empirically supported psychosocial treatment, Acceptance and Commitment Therapy, in facilitating improved quality of life, benefit-finding, and cortisol rhythm in breast cancer patients in an outpatient clinical oncology setting.
Detailed Description
Previous research indicates that breast cancer patients may demonstrate disrupted diurnal cortisol rhythms compared to healthy individuals, and that these disrupted rhythms may be related to recurrence and earlier mortality in some patients. Interestingly, improvements in cortisol regulation in previous intervention studies for cancer patients have not necessarily been related to decreased distress. Rather, improvements in post-traumatic growth, benefit-finding, and meaningfulness have also accounted for improved neuroendocrine and immunological changes. Traditional breast cancer groups, however, may not adequately address these areas because existing interventions often target the reduction of distress as the primary vehicle to improve psychosocial, quality of life, and biophysical outcomes. Acceptance and Commitment Therapy (ACT) is an empirically-supported, mindfulness-based psychological treatment that has been shown to enhance meaningful behavior change thorough increasing emotional acceptance of difficult psychological experiences such as distress, without the goal of changing or eliminating them. The current study seeks to determine the preliminary effect of an 8-week ACT group in increasing positive life changes and corresponding increase in salivary cortisol slope in 40 distressed breast cancer patients, who will be randomly assigned to ACT or a wait list control group. The hypotheses for the present study include: * Patients receiving ACT will demonstrate improvements in Quality of Life (QoL), Benefit-finding (BF), and health behavior compared to control group participants * ACT participants will demonstrate improvements in mean cortisol levels and cortisol reactivity compared to control group participants * These changes will be the result of increased mindful acceptance of cancer-related distress and meaningful behavior changes, rather than a reduction in distress.
Investigators
Jennifer A. Gregg, PhD
Assistant Professor
San Jose State University
Eligibility Criteria
Inclusion Criteria
- •diagnosis of stage I-III breast cancer
- •prescreen distress score above defined cutoff
- •agreement not to seek other breast cancer support services until study completion
Exclusion Criteria
- •previous cancer
- •prior psychiatric treatment for serious mental health disorder (e.g., hospitalization or formal diagnosis of psychosis, major depressive episode, borderline mental retardation, suicidality, or current substance dependence)
- •current use of medications known to interfere with cortisol levels (e.g., dexamethasone)
- •major concurrent medical disease
Outcomes
Primary Outcomes
salivary cortisol
Time Frame: 3-month follow-up
Secondary Outcomes
- self-reported distress(3-month follow-up)
- self-reported quality of life(3-month follow-up)
- self-reported benefit-finding(3-month follow-up)